Asset Details
Do you wish to reserve the book?
Analysis of the efficacy and factors influencing survival of adjuvant radiotherapy for stage II-III biliary tract carcinoma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Analysis of the efficacy and factors influencing survival of adjuvant radiotherapy for stage II-III biliary tract carcinoma
Do you wish to request the book?
Analysis of the efficacy and factors influencing survival of adjuvant radiotherapy for stage II-III biliary tract carcinoma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Analysis of the efficacy and factors influencing survival of adjuvant radiotherapy for stage II-III biliary tract carcinoma
2023
Overview
Background
To determine the efficacy of adjuvant radiotherapy for stage II–III biliary tract carcinoma.
Methods
We retrospectively analyzed the data of 37 patients who underwent radical resection of biliary tract carcinomas at the Affiliated Hospital of Inner Mongolia Medical University between 2016 and 2020. We analyzed survival differences between patients who did (
n
= 17) and did not (
n
= 20) receive postoperative adjuvant radiotherapy by using Kaplan–Meier analysis. The log-rank test and Cox univariate analysis were used. The Cox proportional risk regression model was used for the multifactorial analysis of factors influencing prognosis.
Results
The median survival time (28.9
vs.
14.5 months) and the 1-year (82.40%
vs.
55.0%) and 2-year survival rates (58.8%
vs.
25.0%) were significantly higher among patients who received adjuvant radiotherapy than among those who did not (
χ
2
= 6.381,
p
= 0.012). Multifactorial analysis showed that pathological tumor type (
p
= 0.004), disease stage (
p
= 0.021), and adjuvant radiotherapy (
p
= 0.001) were independent prognostic factors in biliary tract carcinoma. Subgroup analyses showed that compared to no radiotherapy, adjuvant radiotherapy significantly improved median survival time in patients with stage III disease (21.6
vs.
12.7 months;
p
= 0.017), positive margins (28.9
vs.
10.5 months;
p
= 0.012), and T3 or T4 tumors (26.8
vs.
16.8 months;
p
= 0.037).
Conclusion
Adjuvant radiotherapy significantly improved the survival of patients with biliary tract carcinoma, and is recommended especially for patients with stage III disease, positive surgical margins, or ≥ T3.
Highlights
1. Adjuvant radiotherapy was an independent prognostic factor for stage II–III BTC.
2. Adjuvant radiotherapy improved the survival of patients with stage III BTC.
